Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-22T04:04:20.379Z Has data issue: false hasContentIssue false
  • English
  • Français

Unintended Consequences of Coverage Laws Targeting Cancer Drugs

Published online by Cambridge University Press:  01 January 2021

Maximilian Salcher-Konrad  and
Huseyin Naci
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Independent Articles: Commentary
Information
Journal of Law, Medicine & Ethics , Volume 48 , Issue 3: A Bold Agenda for the Next Steps in Health Reform , Fall 2020 , pp. 552 - 554
Copyright
Copyright © American Society of Law, Medicine and Ethics 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Light, D. W. and Lexchin, J., “Why Do Cancer Drugs Get Such an Easy Ride? Rushed Approvals Result in a Poor Deal for Both Patients and Cancer Research,” BMJ (Online) 350, no. 8007 (2019), available at <https://doi.org/10.1136/bmj.h2068> (last visited Sept. 14, 2020).Google Scholar
Leopold, C., Haffajee, R. L., Lu, C. Y., and Wagner, A. K., “The Complex Cancer Care Coverage Environment – What Is the Role of Legislation? A Case Study from Massachusetts,” The Complex Cancer Care Coverage Environment – What Is the Role of Legislation? A Case Study from Massachusetts, 48, no. 3 (2020): 538–551.Google Scholar
MacLeod, T. E., Harris, A. H., and Mahal, A., “Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers,” The Patient - Patient-Centered Outcomes Research 9, no. 3 (2016): 201–22, available at <https://doi.org/10.1007/s40271-015-0139-7> (last visited Sept. 14, 2020).CrossRefGoogle ScholarPubMed
Zhang, A. D., Puthumana, J., Downing, N. S., Shah, N. D., Krumholz, H. M., and Ross, J. S., “Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017,” JAMA Network Open 3, no. 4 (2020): e203284, available at <https://doi.org/10.1001/jamanetworkopen.2020.3284> (last visited Sept. 14, 2020).CrossRefGoogle ScholarPubMed
Blume-Kohout, M. E. and Sood, N., “Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development,” Journal of Public Economics 97, no. 1 (2013): 327–36, available at <https://doi.org/10.1016/j.jpubeco.2012.10.003> (last visited Sept. 14, 2020).CrossRefGoogle ScholarPubMed
Aitken, M., Kleinrock, M., Nass, D., and Simorellis, A., “Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications,” available at <https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2019> (last visited August 28, 2020.)+(last+visited+August+28,+2020.)>Google Scholar
Hernandez, I., San-Juan-Rodriguez, A., Good, C. B., and Gellad, W. F., “Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018,” JAMA 323, no. 9 (2020): 854–62, available at <https://doi.org/10.1001/jama.2020.1012> (last visited Spet. 14, 2020).CrossRefGoogle ScholarPubMed
Dusetzina, S. B., Huskamp, H. A., and Keating, N. L., “Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019,” JAMA 321, no. 20 (2019): 2025–27, available at <https://doi.org/10.1001/jama.2019.4492> (last visited Sept. 14, 2020).CrossRefGoogle ScholarPubMed
Sommers, B. D. and Kesselheim, A. S., “Massachusetts’ Proposed Medicaid Reforms — Cheaper Drugs and Better Coverage?” New England Journal of Medicine 378, no. 2 (2018): 109–11, available at <https://doi.org/10.1056/NEJMp1714824> (last visited Sept. 14, 2020).Google ScholarPubMed
Chambers, J. D., Kim, D. D., Pope, E. F., Graff, J. S., Wilkinson, C. L., and Neumann, P. J., “Specialty Drug Coverage Varies Across Commercial Health Plans In The US,” Health Affairs 37, no. 7 (2018): 1041–47, available at <https://doi.org/10.1377/hlthaff.2017.1553> (last visited Sept. 14, 2020).CrossRefGoogle ScholarPubMed
Wieseler, B., McGauran, N., and Kaiser, T., “New Drugs: Where Did We Go Wrong and What Can We Do Better?” BMJ 366, no. 8207 (2019): l4340, available at <https://doi.org/10.1136/bmj.l4340> (last visited Sept. 14, 2020).Google ScholarPubMed
Stern, A. D., Pietrulla, F., Herr, A., Kesselheim, A. S, and Sarpatwari, A., “The Impact of Price Regulation on the Availability of New Drugs in Germany,” Health Affairs 38, no. 7 (2019): 1182–87, available at <https://doi.org/10.1377/hlthaff.2018.05142> (last visited Sept. 14, 2020).CrossRefGoogle ScholarPubMed
Dakin, H., Devlin, N., Feng, Y., Rice, N., O’Neill, P., and Parkin, D., “The Influence of Cost-Effectiveness and Other Factors on Nice Decisions,” Health Economics 24, no. 10 (2015): 1256–1271, available at <https://doi.org/10.1002/hec.3086> (last visited Sept. 14, 2020).CrossRefGoogle ScholarPubMed
Jack, A., “Which Way Now for the Cancer Drugs Fund?” BMJ 349, no. 7974 (2014): g5524.CrossRefGoogle ScholarPubMed
Wenzl, M. and Chapman, S., “Performance-Based Managed Entry Agreements for New Medicines in OECD Countries and EU Member States: How They Work and Possible Improvements Going Forward,,” OECD Health Working Papers, no. 115 (2019), available at <https://doi.org/10.1787/6e5e4c0f-en> (last visited Sept. 14, 2020).CrossRef+(last+visited+Sept.+14,+2020).>Google Scholar
Aggarwal, A., Fojo, T., Chamberlain, C., Davis, C., and Sullivan, R., “Do Patient Access Schemes for High-Cost Cancer Drugs Deliver Value to Society?-Lessons from the NHS Cancer Drugs Fund,” Annals of Oncology 28, no. 8 (2017): 1738–1750, available at <https://doi.org/10.1093/annonc/mdx110> (last visited Sept. 14, 2020).CrossRefGoogle ScholarPubMed
H. Macdonald, P. and Goldacre, B., “Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-Sectional Analysis On Publicly Accessible Documentation,” MedRxiv (March 2020), available at <https://doi.org/10.1101/2020.03.06.19014944> (last visited Sept. 14, 2020).CrossRef+(last+visited+Sept.+14,+2020).>Google Scholar
See Wenzl and Chapman, supra note 15.Google Scholar